Opinion

Video

Clinical Attributes of Patients Who Would Benefit From Micronized Abiraterone

Panelists discuss how criteria such as patient comorbidities, disease progression levels, and treatment goals should be considered when selecting the appropriate form of abiraterone for patients with mCRPC, and also explore the potential benefits and drawbacks of using micronized abiraterone in specific patient populations.

  • In your opinion, what criteria should be considered when selecting the appropriate form of abiraterone for patients with mCRPC?
  • What are the potential benefits or drawbacks when using micronized abiraterone in specific patient populations (eg, those with comorbidities or differing levels of disease progression)?

Related Videos
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
Medcast series
Michael Jenson, PA-C, answers a question during a Zoom video interview
Couple talking with doctor | Image Credit: © Chinnapong - stock.adobe.com
Andrew C. Peterson, MD, MPH, answers a question during a Zoom interview
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
Oliver Sartor, MD, is featured in this series.
Man talking with doctor, who is taking notes on a clipboard | Image Credit: © DragonImages - stock.adobe.com
Oliver Sartor, MD, is featured in this series.
Related Content
© 2024 MJH Life Sciences

All rights reserved.